BioNTech aims to develop mRNA-based malaria vaccine

July 26, 2021

https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-aims-develop-mrna-based-malaria-vaccine-2021-07-26/

BioNTech (22UAy.DE) wants to build on its success in COVID-19 by developing the first vaccine for malaria based on mRNA technology and aims to start clinical testing by the end on 2022, in an attempt to eradicate the mosquito-borne illness.

The company is also scouting for suitable mRNA vaccine production sites in Africa, either with partners or on its own, and will receive support from the European Commission, the Bill and Melinda Gates Foundation and other organisations.

Bill Gates, the mRNA vaccine makers including Pfizer/BioNTech and Moderna, and their close allies such as Dr. Tony Fauci of the NIAID are clearly playing fast and loose with human lives in their rush to get these experimental vaccines into our bodies.

The Gates Foundation first bought a position in BioNTech in September 2019, well before the COVID-19 pandemic hit. It invested $55 million in the biotech, with the potential for total funding to reach $100 million. The foundation's goal with this investment was to work with BioNTech to develop vaccines and immunotherapies for preventing HIV and tuberculosis (TB) infection.

BioNTech wasn't the first German biotech to attract the attention of the Gates Foundation. In 2015, the foundation committed to investing $52 million in CureVac (NASDAQ: CVAC). In addition, the Gates Foundation agreed to provide separate funding for several projects to develop vaccines based on CureVac's messenger RNA (mRNA) platform

https://journal-neo.org/2020/11/13/what-s-not-being-said-about-pfizer-coronavirus-vaccine/